CMPS COMPASS Pathways Plc American Depository Shares Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
14:00
Jul 23
Jul 23
Psychedelic stocks poised for asymmetric gains.
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
HIGH
17:38
Jul 16
Jul 16
Buy CMPS as a cheaper, more clinically advanced alternative to LLY and ATAI in the psychedelic/mental health space, with notable institutional fund interest per the parent thread context endorsed by the author.
MED
13:50
Jul 05
Jul 05
Author notes CMPS is up ~100%+ YTD and states 'It’s still a sector I like over the long run' with a belief in enormous addressable market for psychedelic therapies.
Author notes CMPS is up ~100%+ YTD and states 'It’s still a sector I like over the long run' with a belief in enormous addressable market for psychedelic therapies.
Risk: Regulatory setbacks or slower-than-expected adoption could reverse gains; valuation may be stretched after large run-up.
21:19
Jun 09
Jun 09
Buy CMPS on the catalyst that psilocybin microdoses may treat obesity, fatty liver, and diabetes — a significant new indication that could dramatically expand the addressable market if regulatory/pharma opposition doesn't block development.
MED
21:57
Jun 08
Jun 08
Author endorses psychedelic stocks as a good sector to be long with massive upside potential, but does not state a personal position in the specific tickers.
08:21
May 18
May 18
Compass Pathways is developing psychedelic therapy for treatment-resistant depression. Commenter (MD/PhD) claims it may lead a paradigm shift. Small-cap biotech with a novel, high-potential pipeline; if FDA approval path clears, significant upside. A speculative early-stage biotech bet on a new treatment class; high risk/reward. Regulatory rejection, clinical trial failures, competitive landscape (e.g., MAPS), capital dilution.
LOW
05:43
Apr 19
Apr 19
Compass Pathways (CMPS) is listed as one of the author's holdings poised to benefit from accelerated psychedelic therapy approvals. The author's logic is that sector-wide positive news will lift all boats in the psychedelic biotech space. A generic long bet on the sector, tied to a vague political headline. CMPS has its own clinical trial risks. The post's catalyst is not specific to CMPS. Stock performance may not correlate with political news.
MED
18:29
Mar 15
Mar 15
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
About CMPS Analyst Coverage
Buzzberg tracks CMPS (COMPASS Pathways Plc American Depository Shares) across 6 sources. 5 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (62%). 8 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Chris Irons, incomesharks, Quoth the Raven.